Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Phase 1 Trial of the LSD1 Inhibitor SP-2577 (Seclidemstat) in Patients With Advanced Solid Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03895684
Recruitment Status : Completed
First Posted : March 29, 2019
Last Update Posted : October 18, 2021
Information provided by (Responsible Party):
Salarius Pharmaceuticals, LLC

No Study Results Posted on for this Study
Recruitment Status : Completed
Actual Primary Completion Date : April 13, 2021
Actual Study Completion Date : April 13, 2021